Trial · NCT02810418
Participant flow84
How many started, completed or left each group, period by period.
1 to 20 of 84
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Arm A Dose Escalation | STARTED | Arm A1, Dose Level 1, Phase I Short Infusion 100µg/kg LMB-100 | 6 | |
| Arm A Dose Escalation | STARTED | Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100 | 8 | |
| Arm A Dose Escalation | STARTED | Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100 | 0 | |
| Arm A Dose Escalation | STARTED | Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in | 0 | |
| Arm A Dose Escalation | STARTED | Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in | 0 | |
| Arm A Dose Escalation | STARTED | Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in | 0 | |
| Arm A Dose Escalation | STARTED | Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg | 0 | |
| Arm A Dose Escalation | COMPLETED | Arm A1, Dose Level 1, Phase I Short Infusion 100µg/kg LMB-100 | 4 | |
| Arm A Dose Escalation | COMPLETED | Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100 | 7 | |
| Arm A Dose Escalation | COMPLETED | Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100 | 0 | |
| Arm A Dose Escalation | COMPLETED | Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in | 0 | |
| Arm A Dose Escalation | COMPLETED | Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in | 0 | |
| Arm A Dose Escalation | COMPLETED | Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in | 0 | |
| Arm A Dose Escalation | COMPLETED | Arm B2, Phase I 24-hr Continuous Infusion Combo Therapy 100µg/kg | 0 | |
| Arm A Dose Escalation | NOT COMPLETED | Arm A1, Dose Level 1, Phase I Short Infusion 100µg/kg LMB-100 | 2 | |
| Arm A Dose Escalation | NOT COMPLETED | Arm A1, Dose Level-1, Phase I Short Infusion 65µg/kg LMB-100 | 1 | |
| Arm A Dose Escalation | NOT COMPLETED | Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100 | 0 | |
| Arm A Dose Escalation | NOT COMPLETED | Arm B1, Dose Level 2, Phase I 48-hr Continuous Infusion Single Agent Lead-in | 0 | |
| Arm A Dose Escalation | NOT COMPLETED | Arm B1, Dose Level 1, Phase I 48-hr Continuous Infusion Single Agent Lead-in | 0 | |
| Arm A Dose Escalation | NOT COMPLETED | Arm B1, Dose Level 3R, Phase I 24-hr Continuous Infusion Single Agent Lead-in | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02810418/flow